Pricing Flexibility: Four Strategies for the Future
This article was originally published in RPM Report
You may also be interested in...
An Eye for an Eye: Lucentis and the New Pharmaceutical Value System
A head- to- head trial of Genentech’s Avastin v. Lucentis raises the stakes in the debate over drug pricing. While previous large comparative trials have focused on a number of different drugs--old against new--the Avastin study is evaluating two brand new cutting edge technologies, one for off-label use. Genentech is not alone in finding this unsettling.
Show Me the Value
As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.
Show Me the Value
As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.